Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment1 SCORE is a retrospective, observational...

In today's rapidly evolving world, access to arts education is more essential than ever. While STEM fields (science, technology, engineering, and math) often receive the bulk of attention in...

SOUL study showed Rybelsus® (semaglutide) tablets 14 mg reduced the risk of major adverse cardiovascular events (MACE) by 14% (ARR 2% absolute risk reduction at 3 years) vs placebo in adults with...

Eoptolink Technology Inc., Ltd. (SZSE: 300502), a leading innovator and provider of advanced optical transceiver solutions, is demonstrating its 1.6T multimode transceiver operating at 212Gb/s per...

Eoptolink Technology Inc., Ltd. (SZSE: 300502), a leading innovator and provider of advanced optical transceiver solutions, will be demonstrating its second generation of fully retimed 1.6T OSFP...